Skip to main content
PMC home page
The BMJ logoLink to The BMJ
editorial
. 1992 May 9;304(6836):1198–1199. doi: 10.1136/bmj.304.6836.1198

Medical treatment for benign prostatic hyperplasia.

C Chapple
PMCID: PMC1881763  PMID: 1381250

Full text

PDF
1198

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrams P. H., Shah P. J., Stone R., Choa R. G. Bladder outflow obstruction treated with phenoxybenzamine. Prog Clin Biol Res. 1981;78:269–275. [PubMed] [Google Scholar]
  2. Caine M., Perlberg S., Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978 Dec;50(7):551–554. doi: 10.1111/j.1464-410x.1978.tb06210.x. [DOI] [PubMed] [Google Scholar]
  3. Caine M., Raz S., Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol. 1975 Apr;47(2):193–202. doi: 10.1111/j.1464-410x.1975.tb03947.x. [DOI] [PubMed] [Google Scholar]
  4. Catalona W. J., Smith D. S., Ratliff T. L., Dodds K. M., Coplen D. E., Yuan J. J., Petros J. A., Andriole G. L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991 Apr 25;324(17):1156–1161. doi: 10.1056/NEJM199104253241702. [DOI] [PubMed] [Google Scholar]
  5. Chapple C. R., Aubry M. L., James S., Greengrass P. M., Burnstock G., Turner-Warwick R. T., Milroy E. J., Davey M. J. Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation. Br J Urol. 1989 May;63(5):487–496. doi: 10.1111/j.1464-410x.1989.tb05942.x. [DOI] [PubMed] [Google Scholar]
  6. Chapple C. R., Christmas T. J., Milroy E. J. A twelve-week placebo-controlled study of prazosin in the treatment of prostatic obstruction. Urol Int. 1990;45 (Suppl 1):47–55. doi: 10.1159/000282030. [DOI] [PubMed] [Google Scholar]
  7. Hedlund H., Andersson K. E., Ek A. Effects of prazosin in patients with benign prostatic obstruction. J Urol. 1983 Aug;130(2):275–278. doi: 10.1016/s0022-5347(17)51106-4. [DOI] [PubMed] [Google Scholar]
  8. Jardin A., Bensadoun H., Delauche-Cavallier M. C., Attali P. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. Lancet. 1991 Jun 15;337(8755):1457–1461. doi: 10.1016/0140-6736(91)93140-5. [DOI] [PubMed] [Google Scholar]
  9. Kawabe K., Ueno A., Takimoto Y., Aso Y., Kato H. Use of an alpha 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. YM617 Clinical Study Group. J Urol. 1990 Oct;144(4):908–912. doi: 10.1016/s0022-5347(17)39620-9. [DOI] [PubMed] [Google Scholar]
  10. Kirby R. S., Coppinger S. W., Corcoran M. O., Chapple C. R., Flannigan M., Milroy E. J. Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. Br J Urol. 1987 Aug;60(2):136–142. doi: 10.1111/j.1464-410x.1987.tb04950.x. [DOI] [PubMed] [Google Scholar]
  11. Ramsay J. W., Scott G. I., Whitfield H. N. A double-blind controlled trial of a new alpha-1 blocking drug in the treatment of bladder outflow obstruction. Br J Urol. 1985 Dec;57(6):657–659. doi: 10.1111/j.1464-410x.1985.tb07026.x. [DOI] [PubMed] [Google Scholar]
  12. Stott M. A., Abrams P. Indoramin in the treatment of prostatic bladder outflow obstruction. Br J Urol. 1991 May;67(5):499–501. doi: 10.1111/j.1464-410x.1991.tb15194.x. [DOI] [PubMed] [Google Scholar]
  13. Thien T., Delaere K. P., Debruyne F. M., Koene R. A. Urinary incontinence caused by prazosin. Br Med J. 1978 Mar 11;1(6113):622–623. doi: 10.1136/bmj.1.6113.622-a. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES